本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Inozyme Pharma

4.00
0.0000
成交量:- -
成交額:- -
市值:2.60億
市盈率:-2.38
高:4.00
開:4.00
低:4.00
收:4.00
資料載入中...
2025/07/01

交易所摘牌聲明

Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
2025/07/01

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/07/01

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/07/01

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/07/01

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/07/01

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/07/01

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/07/01

重要事件披露

Form 8-K - Current report
2025/06/21

重要事件披露

Form 8-K - Current report
2025/06/02

重要事件披露

Form 8-K - Current report
2025/05/16

重要事件披露

Form 8-K - Current report
2025/05/14

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2025/05/14

重要事件披露

Form 8-K - Current report
2025/03/11

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2025/03/10

年度報告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2025/03/10

重要事件披露

Form 8-K - Current report
2025/01/10

重要事件披露

Form 8-K - Current report
2024/12/10

超過5%披露

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
2024/11/14

超過5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/11/05

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]